



Public Meeting on Over-The-Counter Monograph Drug User Fee Program (OMUFA) Reauthorization

September 28, 2023

- 9:00–9:05 AM **Welcome and Introduction**
- 9:05–9:15 AM **Opening Remarks**
Patrizia Cavazzoni, Center for Drug Evaluation and Research, FDA
Center Director
- 9:15–9:45 AM **OMUFA Background and Reauthorization Process**
Karen Murry, Center for Drug Evaluation and Research, FDA
Deputy Director, Office of Non-Prescription Drugs (ONPD)
- 9:45–10:20 AM **Panel 1 – Health Care Professional Perspectives**
James Baumberger, American Academy of Pediatrics
Senior Director, Federal Advocacy
Heather Boyd, American Pharmacists Association
Director, Health Policy
Jessica Satterfield, National Community Pharmacists Association
Associate Director, Policy and Pharmacy Affairs
- 10:20–10:30 AM **Panel 2 – Consumer/Patient Perspectives**
Diana Zuckerman, National Center for Health Research
President
- 10:30–10:50 AM **Break**
- 10:50–11:50 AM **Panel 3 – Regulated Industry Perspectives**
Lisa Parks, Consumer Healthcare Products Association
Senior Vice President, Regulatory and Scientific Affairs
Dan Selechnik, Fragrance Creators Association
Director of Regulatory Science
Douglas Troutman, American Cleaning Institute
General Counsel, Corporate Secretary, and Senior Vice President, Government Affairs
Meredith Petillo, Independent Beauty Association
Senior Director, Technical and Regulatory Affairs



Tom Myers, Personal Care Products Council
Executive Vice President, Legal and General Counsel

Cornell Stamoran, Pharma & Biopharma Outsourcing Association (PBOA)
Vice President, Corporate Strategy and Government Affairs, Catalent Pharma

11:50 AM –12:20 PM **Panel 4 – Scientific and Academic Expert Perspectives**

Eric P. Brass, University of California, Los Angeles (UCLA)
Professor Emeritus of Medicine

Ruth Parker, Emory University
Professor Emerita of Medicine

Maria Coyle, The Ohio State University College of Pharmacy
Associate Professor – Clinical

12:20–12:30 PM **Closing Comments**

Theresa Michele, Center for Drug Evaluation and Research, FDA
Director, Office of Non-Prescription Drugs (ONPD)